[
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Initial Analysis",
    "section": "",
    "text": "Project Summary\nThe project is an institutional review through Georgetown MedStar’s Neuro-Oncology clinic. We have approximately 300 glioblastoma patients diagnosed between 2021 and 2024.\n\nIn 2021, the WHO updated their classification for glioblastomas which prompted a need for updated research. This study uniquely includes “pure” glioblastomas. Therefore, our goal is to learn as much as we can about the disease under the new classifications.\n\n\nWhere I’m Stuck\nAs expected, because our goal is to learn and I am the biostatistician on the study, there has been little guidance for the analysis. So far, I have run K-M and Cox models on all the variables and have figured out which are independently significant, and have also explored the relationship between two specific variables my PI wanted me to. Where to go next is where I am getting stuck. I am trying to efficiently find insights and ensure I am fully exploring the data set without wasting my time."
  },
  {
    "objectID": "eda.html",
    "href": "eda.html",
    "title": "Initial Analysis",
    "section": "",
    "text": "This is my preliminary EDA. It’s what I presented to the doctor (and I will update this) so it’s not on every variable and not as extensive as the gtsummary on the data summary page.\n\n\n\n\n\n\n\n\n\n\n\n\nGender\nCount\n\n\n\n\nFemale\n105\n\n\nMale\n174\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nStatistic\nValue\n\n\n\n\nMin.\n31.00000\n\n\n1st Qu.\n59.00000\n\n\nMedian\n66.00000\n\n\nMean\n65.45878\n\n\n3rd Qu.\n74.00000\n\n\nMax.\n91.00000\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nStatus\nCount\n\n\n\n\nalive\n43\n\n\ndead\n204\n\n\nlost to follow up\n32\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCycles\nCount\nPercentage\n\n\n\n\n0\n68\n25.47\n\n\n&lt;1\n18\n6.74\n\n\n1\n168\n62.92\n\n\n&lt;2\n6\n2.25\n\n\n2\n6\n2.25\n\n\n≥3\n1\n0.37\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCycles\nCount\nPercentage\n\n\n\n\n0\n86\n32.33\n\n\n&lt;1\n19\n7.14\n\n\n1\n57\n21.43\n\n\n&lt;2\n3\n1.13\n\n\n2\n16\n6.02\n\n\n≥3\n85\n31.95\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCycles\nCount\n\n\n\n\nno\n93\n\n\nyes\n162\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nStatistics\nValue\n\n\n\n\nMin.\n1.000000\n\n\n1st Qu.\n4.000000\n\n\nMedian\n6.000000\n\n\nMean\n7.997297\n\n\n3rd Qu.\n8.000000\n\n\nMax.\n267.000000\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nLobes\nCount\n\n\n\n\n0\n18\n\n\n1\n166\n\n\n2\n81\n\n\n3\n12\n\n\n4\n2\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nmicrovascular_proliferation\nCount\n\n\n\n\nno\n82\n\n\nunknown\n1\n\n\nyes\n193\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nnecrosis\nCount\n\n\n\n\nno\n46\n\n\nyes\n232\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\ncaris\nCount\n\n\n\n\nno\n202\n\n\nyes\n74\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nEGFR_amplification\nCount\n\n\n\n\nno\n54\n\n\nunknown\n1\n\n\nyes\n24\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nchromosomal710\nCount\n\n\n\n\nno\n50\n\n\nyes\n21\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTERT_promoter\nCount\n\n\n\n\nno\n13\n\n\nyes\n67\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\npTERT_variant\nCount\n\n\n\n\nC124T\n38\n\n\nC146T\n12\n\n\ng.1295220T?\n1\n\n\ninconclusive\n1\n\n\nunknown\n1\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nMGMT_methylation\nCount\n\n\n\n\nM\n86\n\n\nUM\n178\n\n\nUM pre RT/TMZ, M post\n1\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nKi67_LI\nCount\n\n\n\n\n15%\n20\n\n\n&lt;15%\n44\n\n\n&gt;15%\n175\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nATRX\nCount\n\n\n\n\ninconclusive\n3\n\n\nloss\n5\n\n\nretained\n224\n\n\nunknown\n8\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nmitotic_activity_increase\nCount\n\n\n\n\n0\n4\n\n\n1to5\n51\n\n\n6to10\n39\n\n\n&gt;10\n30\n\n\natypical\n1\n\n\nbrisk\n5\n\n\ndifficult to find\n2\n\n\ndifficult to identify\n1\n\n\neasily identified\n9\n\n\nfew\n2\n\n\nfrequent\n4\n\n\nidentified\n2\n\n\ninconspicuous\n1\n\n\nincreased\n17\n\n\ninfrequent\n3\n\n\nmany\n5\n\n\nmany occasional\n4\n\n\nmany rare\n1\n\n\nnumerous\n1\n\n\noccasional\n30\n\n\npresent\n5\n\n\nrare\n6\n\n\nscattered\n29\n\n\nseveral\n1\n\n\nsome\n3"
  },
  {
    "objectID": "eda.html#exploratory-data-analysis",
    "href": "eda.html#exploratory-data-analysis",
    "title": "Initial Analysis",
    "section": "",
    "text": "This is my preliminary EDA. It’s what I presented to the doctor (and I will update this) so it’s not on every variable and not as extensive as the gtsummary on the data summary page.\n\n\n\n\n\n\n\n\n\n\n\n\nGender\nCount\n\n\n\n\nFemale\n105\n\n\nMale\n174\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nStatistic\nValue\n\n\n\n\nMin.\n31.00000\n\n\n1st Qu.\n59.00000\n\n\nMedian\n66.00000\n\n\nMean\n65.45878\n\n\n3rd Qu.\n74.00000\n\n\nMax.\n91.00000\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nStatus\nCount\n\n\n\n\nalive\n43\n\n\ndead\n204\n\n\nlost to follow up\n32\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCycles\nCount\nPercentage\n\n\n\n\n0\n68\n25.47\n\n\n&lt;1\n18\n6.74\n\n\n1\n168\n62.92\n\n\n&lt;2\n6\n2.25\n\n\n2\n6\n2.25\n\n\n≥3\n1\n0.37\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCycles\nCount\nPercentage\n\n\n\n\n0\n86\n32.33\n\n\n&lt;1\n19\n7.14\n\n\n1\n57\n21.43\n\n\n&lt;2\n3\n1.13\n\n\n2\n16\n6.02\n\n\n≥3\n85\n31.95\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCycles\nCount\n\n\n\n\nno\n93\n\n\nyes\n162\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nStatistics\nValue\n\n\n\n\nMin.\n1.000000\n\n\n1st Qu.\n4.000000\n\n\nMedian\n6.000000\n\n\nMean\n7.997297\n\n\n3rd Qu.\n8.000000\n\n\nMax.\n267.000000\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nLobes\nCount\n\n\n\n\n0\n18\n\n\n1\n166\n\n\n2\n81\n\n\n3\n12\n\n\n4\n2\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nmicrovascular_proliferation\nCount\n\n\n\n\nno\n82\n\n\nunknown\n1\n\n\nyes\n193\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nnecrosis\nCount\n\n\n\n\nno\n46\n\n\nyes\n232\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\ncaris\nCount\n\n\n\n\nno\n202\n\n\nyes\n74\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nEGFR_amplification\nCount\n\n\n\n\nno\n54\n\n\nunknown\n1\n\n\nyes\n24\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nchromosomal710\nCount\n\n\n\n\nno\n50\n\n\nyes\n21\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTERT_promoter\nCount\n\n\n\n\nno\n13\n\n\nyes\n67\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\npTERT_variant\nCount\n\n\n\n\nC124T\n38\n\n\nC146T\n12\n\n\ng.1295220T?\n1\n\n\ninconclusive\n1\n\n\nunknown\n1\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nMGMT_methylation\nCount\n\n\n\n\nM\n86\n\n\nUM\n178\n\n\nUM pre RT/TMZ, M post\n1\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nKi67_LI\nCount\n\n\n\n\n15%\n20\n\n\n&lt;15%\n44\n\n\n&gt;15%\n175\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nATRX\nCount\n\n\n\n\ninconclusive\n3\n\n\nloss\n5\n\n\nretained\n224\n\n\nunknown\n8\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nmitotic_activity_increase\nCount\n\n\n\n\n0\n4\n\n\n1to5\n51\n\n\n6to10\n39\n\n\n&gt;10\n30\n\n\natypical\n1\n\n\nbrisk\n5\n\n\ndifficult to find\n2\n\n\ndifficult to identify\n1\n\n\neasily identified\n9\n\n\nfew\n2\n\n\nfrequent\n4\n\n\nidentified\n2\n\n\ninconspicuous\n1\n\n\nincreased\n17\n\n\ninfrequent\n3\n\n\nmany\n5\n\n\nmany occasional\n4\n\n\nmany rare\n1\n\n\nnumerous\n1\n\n\noccasional\n30\n\n\npresent\n5\n\n\nrare\n6\n\n\nscattered\n29\n\n\nseveral\n1\n\n\nsome\n3"
  },
  {
    "objectID": "data_summary.html",
    "href": "data_summary.html",
    "title": "Initial Analysis",
    "section": "",
    "text": "Data Summary\nWe collected data for the last 4 months by reading patient charts and manually entering it into a spreadsheet. I cleaned the data in Python and have been running analysis in R. Below is a summary of that data.\n\n\n── Attaching core tidyverse packages ──────────────────────── tidyverse 2.0.0 ──\n✔ dplyr     1.1.4     ✔ readr     2.1.5\n✔ forcats   1.0.0     ✔ stringr   1.5.1\n✔ ggplot2   3.5.1     ✔ tibble    3.2.1\n✔ lubridate 1.9.3     ✔ tidyr     1.3.1\n✔ purrr     1.0.2     \n── Conflicts ────────────────────────────────────────── tidyverse_conflicts() ──\n✖ dplyr::filter() masks stats::filter()\n✖ dplyr::lag()    masks stats::lag()\nℹ Use the conflicted package (&lt;http://conflicted.r-lib.org/&gt;) to force all conflicts to become errors\nNew names:\nRows: 294 Columns: 86\n── Column specification ────────────────────────────────────────────────────────\nDelimiter: \",\"\nchr (76): gender, race, vital_status, institution_type, resection_extent, nu...\ndbl (10): ...1, patient_id, diagnosis_age, exclude, overall_survival, time_s...\n\nℹ Use `spec()` to retrieve the full column specification for this data.\nℹ Specify the column types or set `show_col_types = FALSE` to quiet this message.\n\n\n [1] \"...1\"                        \"patient_id\"                 \n [3] \"gender\"                      \"race\"                       \n [5] \"diagnosis_age\"               \"exclude\"                    \n [7] \"vital_status\"                \"institution_type\"           \n [9] \"overall_survival\"            \"resection_extent\"           \n[11] \"num_surgeries\"               \"num_radiations\"             \n[13] \"num_chemo\"                   \"discontinued_treatment\"     \n[15] \"time_surgery_radiation\"      \"received_stupp\"             \n[17] \"discontinued_stupps\"         \"time_symptoms_diagnosis\"    \n[19] \"time_symptoms_death\"         \"on_treatment_last_visit\"    \n[21] \"num_lobes\"                   \"lobes_involved\"             \n[23] \"other_brain_regions\"         \"unique_clinical_findings\"   \n[25] \"seizures_presentation\"       \"seizures_later\"             \n[27] \"dvt_pe_presentation\"         \"dvt_pe_during\"              \n[29] \"microvascular_proliferation\" \"mp_early\"                   \n[31] \"mp_focal\"                    \"necrosis\"                   \n[33] \"chromosomal710\"              \"EGFR_amplification\"         \n[35] \"TERT_promoter\"               \"pTERT_variant\"              \n[37] \"MGMT_methylation\"            \"Ki67_LI\"                    \n[39] \"ATRX\"                        \"other_mutations\"            \n[41] \"mitotic_activity_increase\"   \"specific_mitotic\"           \n[43] \"caris\"                       \"dna_profile\"                \n[45] \"methylation_result\"          \"lobes_clean\"                \n[47] \"frontal\"                     \"parietal\"                   \n[49] \"temporal\"                    \"occipital\"                  \n[51] \"other_regions_clean\"         \"left insula\"                \n[53] \"subinsular region\"           \"intra-axial\"                \n[55] \"basal ganglia\"               \"brainstem (cerebellum)\"     \n[57] \"centrum semiovale\"           \"hypothalamus\"               \n[59] \"periventricular region\"      \"pontomesencephalic junction\"\n[61] \"midbrain\"                    \"periventricular\"            \n[63] \"peri-insular\"                \"intrahemispheric\"           \n[65] \"spinal cord\"                 \"cerebellum\"                 \n[67] \"postcentral gyrus\"           \"midline\"                    \n[69] \"insula\"                      \"ganglia thalamic capsule\"   \n[71] \"hippocampus\"                 \"corpus callosum\"            \n[73] \"cerebellar peduncle\"         \"optic nerve\"                \n[75] \"falcine dural-based mass\"    \"caudate\"                    \n[77] \"intraventricular\"            \"right lateral ventricle\"    \n[79] \"pons\"                        \"optic tract\"                \n[81] \"parafalcine lesions\"         \"corona radiatia\"            \n[83] \"intraparenchyma\"             \"brainstem\"                  \n[85] \"thalamus\"                    \"status\"                     \n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nN = 2941\n\n\n\n\npatient_id\n148 (74, 222)\n\n\ngender\n\n\n\n\n    Female\n113 (38%)\n\n\n    Male\n181 (62%)\n\n\nrace\n\n\n\n\n    asian\n12 (4.1%)\n\n\n    black\n74 (25%)\n\n\n    other\n13 (4.4%)\n\n\n    unknown\n17 (5.8%)\n\n\n    white\n178 (61%)\n\n\ndiagnosis_age\n67 (59, 75)\n\n\n    Unknown\n3\n\n\nvital_status\n\n\n\n\n    alive\n44 (15%)\n\n\n    dead\n210 (72%)\n\n\n    lost to follow up\n37 (13%)\n\n\n    Unknown\n3\n\n\ninstitution_type\n\n\n\n\n    ER\n232 (82%)\n\n\n    inpatient\n1 (0.4%)\n\n\n    outpatient clinic\n51 (18%)\n\n\n    Unknown\n10\n\n\noverall_survival\n6 (3, 14)\n\n\n    Unknown\n86\n\n\nresection_extent\n\n\n\n\n    Biopsy\n55 (19%)\n\n\n    Gross Total Resection\n34 (12%)\n\n\n    Resection NOS\n174 (61%)\n\n\n    Subtotal Resection\n23 (8.0%)\n\n\n    Unknown\n8\n\n\nnum_surgeries\n\n\n\n\n    ≥3\n7 (2.4%)\n\n\n    0\n1 (0.3%)\n\n\n    1\n233 (81%)\n\n\n    2\n47 (16%)\n\n\n    Unknown\n6\n\n\nnum_radiations\n\n\n\n\n    &lt;1\n18 (6.6%)\n\n\n    &lt;2\n6 (2.2%)\n\n\n    ≥3\n1 (0.4%)\n\n\n    0\n72 (26%)\n\n\n    1\n171 (62%)\n\n\n    2\n6 (2.2%)\n\n\n    Unknown\n20\n\n\nnum_chemo\n\n\n\n\n    &lt;1\n19 (6.9%)\n\n\n    &lt;2\n3 (1.1%)\n\n\n    ≥3\n88 (32%)\n\n\n    0\n91 (33%)\n\n\n    1\n57 (21%)\n\n\n    2\n16 (5.8%)\n\n\n    2- 4 days each\n1 (0.4%)\n\n\n    Unknown\n19\n\n\ndiscontinued_treatment\n38 (18%)\n\n\n    Unknown\n88\n\n\ntime_surgery_radiation\n6.0 (4.0, 8.0)\n\n\n    Unknown\n106\n\n\nreceived_stupp\n165 (63%)\n\n\n    Unknown\n31\n\n\ndiscontinued_stupps\n27 (16%)\n\n\n    Unknown\n122\n\n\ntime_symptoms_diagnosis\n0.50 (0.25, 1.50)\n\n\n    Unknown\n10\n\n\ntime_symptoms_death\n8 (4, 16)\n\n\n    Unknown\n87\n\n\non_treatment_last_visit\n18 (6.2%)\n\n\n    Unknown\n3\n\n\nnum_lobes\n\n\n\n\n    0\n20 (6.9%)\n\n\n    1\n172 (60%)\n\n\n    2\n82 (28%)\n\n\n    3\n12 (4.2%)\n\n\n    4\n2 (0.7%)\n\n\n    Unknown\n6\n\n\nlobes_involved\n\n\n\n\n    frontal\n74 (28%)\n\n\n    frontal, occipital\n1 (0.4%)\n\n\n    frontal, parietal\n18 (6.7%)\n\n\n    Frontal, Parietal, Occipital, Temporal\n1 (0.4%)\n\n\n    frontal, temporal\n16 (6.0%)\n\n\n    frontal, temporal, parietal\n2 (0.7%)\n\n\n    frontal, temporal, temporal\n1 (0.4%)\n\n\n    occipital\n8 (3.0%)\n\n\n    occipital, temporal\n3 (1.1%)\n\n\n    occipital, temporal, frontal\n1 (0.4%)\n\n\n    parietal\n24 (9.0%)\n\n\n    parietal, frontal\n3 (1.1%)\n\n\n    parietal, occipital\n10 (3.7%)\n\n\n    parietal, occipital, frontal\n1 (0.4%)\n\n\n    parietal, occipital, temporal\n3 (1.1%)\n\n\n    parietal, temporal\n4 (1.5%)\n\n\n    parietal, temporal, frontal\n1 (0.4%)\n\n\n    parietal, temporal, occipital\n2 (0.7%)\n\n\n    parietal, temporal, occipital, frontal\n1 (0.4%)\n\n\n    temporal\n65 (24%)\n\n\n    temporal, frontal\n6 (2.2%)\n\n\n    temporal, occipital\n4 (1.5%)\n\n\n    temporal, occiptial\n2 (0.7%)\n\n\n    temporal, parietal\n14 (5.2%)\n\n\n    Temporal, Parietal\n1 (0.4%)\n\n\n    temporal, parietal, occipital\n1 (0.4%)\n\n\n    Unknown\n27\n\n\nother_brain_regions\n\n\n\n\n    basal ganglia\n8 (5.9%)\n\n\n    basal ganglia, corpus callosum\n1 (0.7%)\n\n\n    basal ganglia, corpus callosum, thalamus, ganglia thalamic capsule\n1 (0.7%)\n\n\n    basal ganglia, thalamus\n3 (2.2%)\n\n\n    basal ganglia, thalamus, pons, parafalcine lesions, midbrain\n1 (0.7%)\n\n\n    basil ganglia\n1 (0.7%)\n\n\n    brainstem\n1 (0.7%)\n\n\n    brainstem (cerebellum)\n1 (0.7%)\n\n\n    caudate\n1 (0.7%)\n\n\n    centrum semiovale, basal ganglia, corona radiatia\n1 (0.7%)\n\n\n    cerebellum\n2 (1.5%)\n\n\n    cerebellum, basal ganglia, hippocampus\n1 (0.7%)\n\n\n    cerebellum, thalamus, basil ganglia\n1 (0.7%)\n\n\n    corpus callosum\n25 (19%)\n\n\n    corpus callosum, crosses the midline\n1 (0.7%)\n\n\n    corpus callosum, intra-axial\n2 (1.5%)\n\n\n    corpus callosum, intrahemispheric\n1 (0.7%)\n\n\n    corpus callosum, midline\n2 (1.5%)\n\n\n    corpus callosum, thalamus\n1 (0.7%)\n\n\n    corpus callosum, thalamus, midline\n1 (0.7%)\n\n\n    falcine dural-based mass\n1 (0.7%)\n\n\n    hippocampus, basal ganglia\n1 (0.7%)\n\n\n    hippocampus, basal ganglia, subinsular region, hypothalamus\n1 (0.7%)\n\n\n    hippocampus, insula\n1 (0.7%)\n\n\n    insula\n5 (3.7%)\n\n\n    insula, midline\n2 (1.5%)\n\n\n    insular\n3 (2.2%)\n\n\n    insular cortex, basal ganglia, brainstem, peri-insular, pons, midline\n1 (0.7%)\n\n\n    insular region\n1 (0.7%)\n\n\n    insular, midline\n1 (0.7%)\n\n\n    insular, midline shift, corpus callosum\n1 (0.7%)\n\n\n    intra-axial\n8 (5.9%)\n\n\n    intra-axial, corpus callosum\n1 (0.7%)\n\n\n    intra-axial, midline shift, basil ganglia\n1 (0.7%)\n\n\n    intraparenchyma\n1 (0.7%)\n\n\n    intraventricular\n2 (1.5%)\n\n\n    Intraventricular\n1 (0.7%)\n\n\n    left insula, thalamus\n1 (0.7%)\n\n\n    midbrain, basil ganglia, corpus callosum\n1 (0.7%)\n\n\n    midbrain, corpus callosum\n1 (0.7%)\n\n\n    midline\n8 (5.9%)\n\n\n    midline shift\n4 (3.0%)\n\n\n    midline, corpus callosum\n1 (0.7%)\n\n\n    midline, right lateral ventricle\n1 (0.7%)\n\n\n    N\n4 (3.0%)\n\n\n    optic nerve\n1 (0.7%)\n\n\n    optic nerve, optic tract, hypothalamus, basal ganglia\n1 (0.7%)\n\n\n    periventricular region, corpus callosum\n1 (0.7%)\n\n\n    periventricular, corpus callosum\n1 (0.7%)\n\n\n    pons, cerebellar peduncle\n1 (0.7%)\n\n\n    pontomesenphalic junction\n1 (0.7%)\n\n\n    postcentral gyrus, intra-axial\n1 (0.7%)\n\n\n    spinal cord\n1 (0.7%)\n\n\n    thalamus\n12 (8.9%)\n\n\n    Thalamus\n1 (0.7%)\n\n\n    thalamus, basal ganglia\n1 (0.7%)\n\n\n    thalamus, corpus callosum\n1 (0.7%)\n\n\n    thalamus, hippocampus, insula\n1 (0.7%)\n\n\n    thalamus, midbrain\n1 (0.7%)\n\n\n    thalamus, midbrain, basal ganglia\n1 (0.7%)\n\n\n    Unknown\n159\n\n\nunique_clinical_findings\n\n\n\n\n    basal/squamous cell carcinoma\n1 (2.3%)\n\n\n    Bell's palsy, childhood leukemia\n1 (2.3%)\n\n\n    C-spine injury\n1 (2.3%)\n\n\n    epilepsy s/p right temporal resection 1998\n1 (2.3%)\n\n\n    exposed to agent orange\n1 (2.3%)\n\n\n    extension towards thalamus and splenium\n1 (2.3%)\n\n\n    GI malignancies\n1 (2.3%)\n\n\n    Hx carcinoma\n1 (2.3%)\n\n\n    Hx metastatic sarcomatoid carcinoma\n1 (2.3%)\n\n\n    hx of autonomic neuropathy\n1 (2.3%)\n\n\n    hx of breast cancer\n1 (2.3%)\n\n\n    hx of breast cancer, sickle cell anemia\n1 (2.3%)\n\n\n    Hx of ependymoma\n1 (2.3%)\n\n\n    Hx of esophageal adenocarcinoma\n1 (2.3%)\n\n\n    Hx of harvoni treatment\n1 (2.3%)\n\n\n    Hx of low grade glioma (20 years prior) and IPH\n1 (2.3%)\n\n\n    hx of metastatic breast cancer, lung cancer\n1 (2.3%)\n\n\n    Hx of prostate adenocarcinoma\n1 (2.3%)\n\n\n    Hx of prostate cancer\n3 (6.8%)\n\n\n    Hx of squamous cell carcinoma\n1 (2.3%)\n\n\n    Hx of T-cell lymphoma\n1 (2.3%)\n\n\n    in context of AD\n1 (2.3%)\n\n\n    in context of HIV\n1 (2.3%)\n\n\n    in context of Lynch Syndrome\n1 (2.3%)\n\n\n    in context of melanoma\n1 (2.3%)\n\n\n    in context of NF1\n1 (2.3%)\n\n\n    in context of PD\n1 (2.3%)\n\n\n    Incidental pituitary adenoma\n1 (2.3%)\n\n\n    intraparenchymal\n1 (2.3%)\n\n\n    leptomeningeal carcimatosis\n1 (2.3%)\n\n\n    LMD\n1 (2.3%)\n\n\n    metastatic breast cancer\n1 (2.3%)\n\n\n    N\n1 (2.3%)\n\n\n    parkinson's\n1 (2.3%)\n\n\n    parkinsons, dementia\n1 (2.3%)\n\n\n    PMH of brainstem tumor\n1 (2.3%)\n\n\n    recurrent synovial sarcoma\n1 (2.3%)\n\n\n    sarcomatous features\n2 (4.5%)\n\n\n    sarcomous features\n1 (2.3%)\n\n\n    Sjogren's syndrome\n1 (2.3%)\n\n\n    tumour crosses the midline\n1 (2.3%)\n\n\n    Unknown\n250\n\n\nseizures_presentation\n\n\n\n\n    no\n216 (75%)\n\n\n    unclear\n2 (0.7%)\n\n\n    yes\n71 (25%)\n\n\n    Unknown\n5\n\n\nseizures_later\n\n\n\n\n    no\n184 (66%)\n\n\n    unclear\n2 (0.7%)\n\n\n    yes\n94 (34%)\n\n\n    Unknown\n14\n\n\ndvt_pe_presentation\n8 (2.8%)\n\n\n    Unknown\n4\n\n\ndvt_pe_during\n53 (19%)\n\n\n    Unknown\n12\n\n\nmicrovascular_proliferation\n\n\n\n\n    no\n91 (31%)\n\n\n    unknown\n1 (0.3%)\n\n\n    yes\n197 (68%)\n\n\n    Unknown\n5\n\n\nmp_early\n13 (6.2%)\n\n\n    Unknown\n84\n\n\nmp_focal\n21 (10.0%)\n\n\n    Unknown\n83\n\n\nnecrosis\n237 (81%)\n\n\n    Unknown\n3\n\n\nchromosomal710\n23 (30%)\n\n\n    Unknown\n217\n\n\nEGFR_amplification\n\n\n\n\n    no\n61 (71%)\n\n\n    unknown\n1 (1.2%)\n\n\n    yes\n24 (28%)\n\n\n    Unknown\n208\n\n\nTERT_promoter\n70 (80%)\n\n\n    Unknown\n206\n\n\npTERT_variant\n\n\n\n\n    C124T\n40 (73%)\n\n\n    C146T\n12 (22%)\n\n\n    g.1295220T?\n1 (1.8%)\n\n\n    inconclusive\n1 (1.8%)\n\n\n    unknown\n1 (1.8%)\n\n\n    Unknown\n239\n\n\nMGMT_methylation\n\n\n\n\n    M\n90 (32%)\n\n\n    UM\n186 (67%)\n\n\n    UM pre RT/TMZ, M post\n1 (0.4%)\n\n\n    Unknown\n17\n\n\nKi67_LI\n\n\n\n\n    &lt;15%\n48 (19%)\n\n\n    &gt;15%\n182 (73%)\n\n\n    15%\n20 (8.0%)\n\n\n    Unknown\n44\n\n\nATRX\n\n\n\n\n    inconclusive\n3 (1.2%)\n\n\n    loss\n7 (2.8%)\n\n\n    retained\n235 (93%)\n\n\n    unknown\n8 (3.2%)\n\n\n    Unknown\n41\n\n\nother_mutations\n\n\n\n\n    AKT3, EGFRvIII, MTAP deletion, CDKN2A/B deletion\n1 (1.2%)\n\n\n    ATM, TP53\n1 (1.2%)\n\n\n    ATRX mutation, CDKN2A/B deletion, and PDGFRA amplification\n1 (1.2%)\n\n\n    ATRX, PPMD1, PDGFRA amplified, KDR (VEGFR2), KIT\n1 (1.2%)\n\n\n    BRAF V600E pathogenic variant, CDKN2A/B deletion\n1 (1.2%)\n\n\n    BRCA1, NF1, PTEN (PIK3R1)\n1 (1.2%)\n\n\n    BRCA2, ATRX, PT53, PDGFRA, PTEN, SETD2, mismatch repair genes (MLH1, MSH2, MSH6 and POLE)\n1 (1.2%)\n\n\n    CDK4 amp, PTEN, MDM2_FRS2 amplification\n1 (1.2%)\n\n\n    CDKN2A deep deletion\n1 (1.2%)\n\n\n    CDKN2A/B deletion, MTAP deletion, NTRK2 fusion, ATM\n1 (1.2%)\n\n\n    CDKN2A/B deletion, MTAP deletion, PDGFRA\n1 (1.2%)\n\n\n    CDKN2A/B, EGFR, PIK3CA, SETD2\n1 (1.2%)\n\n\n    CDKN2A/B, TP53, PTEN\n1 (1.2%)\n\n\n    DKN2A/B deleted, MTAP deleted, PTEN, EGFR, EGFRvIII\n1 (1.2%)\n\n\n    DNMT3A, MSH6, PPP2R1A, PTEN\n1 (1.2%)\n\n\n    EGFR\n4 (4.7%)\n\n\n    EGFR, NOTCH1, CDKN2A/B and MTAP deletion\n1 (1.2%)\n\n\n    EGFR, PIK3CA\n1 (1.2%)\n\n\n    EGFR, PTEN\n1 (1.2%)\n\n\n    EGFR, PTEN, BCOR, MTOR, PIK3CA\n1 (1.2%)\n\n\n    EGFR, PTEN, NF1, PTPN11\n1 (1.2%)\n\n\n    EGFR, TP53\n1 (1.2%)\n\n\n    EGFRvIII, CDKN2A/B and MTAP deletion\n1 (1.2%)\n\n\n    EGFRvIII, CDKN2B deletion, CREBBP\n1 (1.2%)\n\n\n    EGFRvIII, EGFR\n1 (1.2%)\n\n\n    FGFR1\n1 (1.2%)\n\n\n    FGFR3, PTEN\n1 (1.2%)\n\n\n    H3K27M\n1 (1.2%)\n\n\n    H3K27me3\n1 (1.2%)\n\n\n    IDH\n1 (1.2%)\n\n\n    MDM2 amplified\n1 (1.2%)\n\n\n    MTAP, PTEN\n1 (1.2%)\n\n\n    NF, PDGFRA, KDR, KIT\n1 (1.2%)\n\n\n    NF1\n3 (3.5%)\n\n\n    NF1, FGFR2, ARID2\n1 (1.2%)\n\n\n    NF1, MDM2 amplification, CDK4 amplification\n1 (1.2%)\n\n\n    NF1, PIK3R1\n1 (1.2%)\n\n\n    NF1, PPM1D, KRAS\n1 (1.2%)\n\n\n    NF1, PTEN\n1 (1.2%)\n\n\n    NF1, PTEN, FANCD2, TP53\n1 (1.2%)\n\n\n    NF1, PTPN11\n1 (1.2%)\n\n\n    NF1, RET, ROS1\n1 (1.2%)\n\n\n    NF1, SETD2, MTAP deletion, CDKN2A/B deletion\n1 (1.2%)\n\n\n    PDGFRA amplification, CDKN2A/B homozygous deletion, CREBBP pathogenic variant\n1 (1.2%)\n\n\n    PDGFRA, EGFRvIII, PTEN\n1 (1.2%)\n\n\n    PDGFRalpha amplified, CDKN2A homozygous loss\n1 (1.2%)\n\n\n    PIK3CA\n1 (1.2%)\n\n\n    PIK3CA, ACVR1\n1 (1.2%)\n\n\n    PIK3CA, DNMT3A\n1 (1.2%)\n\n\n    PIK3CA, NF1\n1 (1.2%)\n\n\n    PIK3CA, PTPN11\n1 (1.2%)\n\n\n    PTEN\n2 (2.4%)\n\n\n    PTEN deletion, CDKN2A/B deletion, MTAP deletion\n1 (1.2%)\n\n\n    PTEN loss\n1 (1.2%)\n\n\n    PTEN loss, TP53\n1 (1.2%)\n\n\n    PTEN, CDC73, NTRK2 fusion\n1 (1.2%)\n\n\n    PTEN, EGFR\n1 (1.2%)\n\n\n    PTEN, EGFRvIII\n1 (1.2%)\n\n\n    PTEN, EGFRvIII, EGFR, CDK4, MDM2\n1 (1.2%)\n\n\n    PTEN, NF1\n2 (2.4%)\n\n\n    PTEN, PIK3CA, MTOR\n1 (1.2%)\n\n\n    PTEN, PIK3R1\n1 (1.2%)\n\n\n    PTPN11\n2 (2.4%)\n\n\n    RB1, PRKDC, PDGFRA\n1 (1.2%)\n\n\n    SPRED1, TRAF7\n1 (1.2%)\n\n\n    TP53 mt, CDK4 amp\n1 (1.2%)\n\n\n    TP53, CDKN2A/B deletion, MTAP deletion, IDH1/2 mutation\n1 (1.2%)\n\n\n    TP53, deletions of CDKN2A, CDKN2B, BRCA1, and MTAP, fusion of PVT1\n1 (1.2%)\n\n\n    TP53, DNMT3A\n1 (1.2%)\n\n\n    TP53, EGFRvIII, PTEN deletion, EGFR\n1 (1.2%)\n\n\n    TP53, IDH2 likely benign variant, EGFR\n1 (1.2%)\n\n\n    TP53, PDGFRA, CDK4, HMGA2, KDR (VEGFR2), KIT\n1 (1.2%)\n\n\n    TP53, PIK3CA, RB1\n1 (1.2%)\n\n\n    TP53, PTEN\n2 (2.4%)\n\n\n    TP53, PTEN, F1, FGFR3-TACC3\n1 (1.2%)\n\n\n    TP53, RB1, and SETD2\n1 (1.2%)\n\n\n    Unknown\n209\n\n\nmitotic_activity_increase\n\n\n\n\n    &gt;10\n30 (11%)\n\n\n    0\n5 (1.9%)\n\n\n    1to5\n55 (21%)\n\n\n    6to10\n40 (15%)\n\n\n    atypical\n1 (0.4%)\n\n\n    brisk\n5 (1.9%)\n\n\n    difficult to find\n3 (1.1%)\n\n\n    difficult to identify\n1 (0.4%)\n\n\n    easily identified\n9 (3.4%)\n\n\n    few\n2 (0.7%)\n\n\n    frequent\n4 (1.5%)\n\n\n    identified\n2 (0.7%)\n\n\n    inconspicuous\n1 (0.4%)\n\n\n    increased\n19 (7.1%)\n\n\n    infrequent\n3 (1.1%)\n\n\n    many\n5 (1.9%)\n\n\n    many occasional\n4 (1.5%)\n\n\n    many rare\n1 (0.4%)\n\n\n    numerous\n1 (0.4%)\n\n\n    occasional\n31 (12%)\n\n\n    present\n5 (1.9%)\n\n\n    rare\n7 (2.6%)\n\n\n    scattered\n30 (11%)\n\n\n    several\n1 (0.4%)\n\n\n    some\n3 (1.1%)\n\n\n    Unknown\n26\n\n\nspecific_mitotic\n\n\n\n\n    0\n5 (3.8%)\n\n\n    1\n1 (0.8%)\n\n\n    10\n4 (3.1%)\n\n\n    11\n6 (4.6%)\n\n\n    12\n7 (5.4%)\n\n\n    13\n4 (3.1%)\n\n\n    14\n2 (1.5%)\n\n\n    15\n1 (0.8%)\n\n\n    16\n2 (1.5%)\n\n\n    19\n1 (0.8%)\n\n\n    2\n6 (4.6%)\n\n\n    20\n3 (2.3%)\n\n\n    21\n2 (1.5%)\n\n\n    2to3\n11 (8.5%)\n\n\n    3\n9 (6.9%)\n\n\n    3to4\n5 (3.8%)\n\n\n    4\n5 (3.8%)\n\n\n    4to5\n12 (9.2%)\n\n\n    5\n6 (4.6%)\n\n\n    5to6\n2 (1.5%)\n\n\n    6\n13 (10%)\n\n\n    7\n10 (7.7%)\n\n\n    7to8\n1 (0.8%)\n\n\n    8\n5 (3.8%)\n\n\n    8to9\n1 (0.8%)\n\n\n    9\n4 (3.1%)\n\n\n    at least 10\n2 (1.5%)\n\n\n    Unknown\n164\n\n\ncaris\n77 (27%)\n\n\n    Unknown\n9\n\n\ndna_profile\n13 (4.6%)\n\n\n    Unknown\n13\n\n\nmethylation_result\n\n\n\n\n    corroborates diagnosis\n1 (7.1%)\n\n\n    corroborates diagnosis; mesenchymal subtype\n1 (7.1%)\n\n\n    corroborates GBM diagnosis\n1 (7.1%)\n\n\n    high grade neuroepithelial subtype E\n1 (7.1%)\n\n\n    indicative of high grade glioma\n1 (7.1%)\n\n\n    insufficient DNA\n1 (7.1%)\n\n\n    mesenchymal subtype; NTRK fusion\n1 (7.1%)\n\n\n    mesenchymal type\n1 (7.1%)\n\n\n    no subtype match- infiltrating lioma NEC\n1 (7.1%)\n\n\n    Not uploaded\n1 (7.1%)\n\n\n    RTK I\n1 (7.1%)\n\n\n    RTK II- DNA methylation\n1 (7.1%)\n\n\n    subtype E\n2 (14%)\n\n\n    Unknown\n280\n\n\nlobes_clean\n\n\n\n\n    ['frontal', 'occipital']\n1 (0.3%)\n\n\n    ['frontal', 'parietal', 'occipital', 'temporal']\n1 (0.3%)\n\n\n    ['frontal', 'parietal']\n18 (6.1%)\n\n\n    ['frontal', 'temporal', 'parietal']\n2 (0.7%)\n\n\n    ['frontal', 'temporal']\n17 (5.8%)\n\n\n    ['frontal']\n74 (25%)\n\n\n    ['occipital', 'temporal', 'frontal']\n1 (0.3%)\n\n\n    ['occipital', 'temporal']\n3 (1.0%)\n\n\n    ['occipital']\n8 (2.7%)\n\n\n    ['parietal', 'frontal']\n3 (1.0%)\n\n\n    ['parietal', 'occipital', 'frontal']\n1 (0.3%)\n\n\n    ['parietal', 'occipital', 'temporal']\n3 (1.0%)\n\n\n    ['parietal', 'occipital']\n10 (3.4%)\n\n\n    ['parietal', 'temporal', 'frontal']\n1 (0.3%)\n\n\n    ['parietal', 'temporal', 'occipital', 'frontal']\n1 (0.3%)\n\n\n    ['parietal', 'temporal', 'occipital']\n2 (0.7%)\n\n\n    ['parietal', 'temporal']\n4 (1.4%)\n\n\n    ['parietal']\n24 (8.2%)\n\n\n    ['temporal', 'frontal']\n6 (2.0%)\n\n\n    ['temporal', 'occipital']\n6 (2.0%)\n\n\n    ['temporal', 'parietal', 'occipital']\n1 (0.3%)\n\n\n    ['temporal', 'parietal']\n15 (5.1%)\n\n\n    ['temporal']\n65 (22%)\n\n\n    []\n27 (9.2%)\n\n\nfrontal\n126 (43%)\n\n\nparietal\n86 (29%)\n\n\ntemporal\n128 (44%)\n\n\noccipital\n38 (13%)\n\n\nother_regions_clean\n\n\n\n\n    ['basal ganglia', 'corpus callosum', 'thalamus', 'ganglia thalamic capsule']\n1 (0.3%)\n\n\n    ['basal ganglia', 'corpus callosum']\n1 (0.3%)\n\n\n    ['basal ganglia', 'thalamus', 'pons', 'parafalcine lesions', 'midbrain']\n1 (0.3%)\n\n\n    ['basal ganglia', 'thalamus']\n3 (1.0%)\n\n\n    ['basal ganglia']\n9 (3.1%)\n\n\n    ['brainstem (cerebellum)']\n1 (0.3%)\n\n\n    ['brainstem']\n1 (0.3%)\n\n\n    ['caudate']\n1 (0.3%)\n\n\n    ['centrum semiovale', 'basal ganglia', 'corona radiatia']\n1 (0.3%)\n\n\n    ['cerebellum', 'basal ganglia', 'hippocampus']\n1 (0.3%)\n\n\n    ['cerebellum', 'thalamus', 'basal ganglia']\n1 (0.3%)\n\n\n    ['cerebellum']\n2 (0.7%)\n\n\n    ['corpus callosum', 'intra-axial']\n2 (0.7%)\n\n\n    ['corpus callosum', 'intrahemispheric']\n1 (0.3%)\n\n\n    ['corpus callosum', 'midline']\n3 (1.0%)\n\n\n    ['corpus callosum', 'thalamus', 'midline']\n1 (0.3%)\n\n\n    ['corpus callosum', 'thalamus']\n1 (0.3%)\n\n\n    ['corpus callosum']\n25 (8.5%)\n\n\n    ['falcine dural-based mass']\n1 (0.3%)\n\n\n    ['hippocampus', 'basal ganglia', 'subinsular region', 'hypothalamus']\n1 (0.3%)\n\n\n    ['hippocampus', 'basal ganglia']\n1 (0.3%)\n\n\n    ['hippocampus', 'insula']\n1 (0.3%)\n\n\n    ['insula', 'basal ganglia', 'brainstem', 'peri-insular', 'pons', 'midline']\n1 (0.3%)\n\n\n    ['insula', 'midline', 'corpus callosum']\n1 (0.3%)\n\n\n    ['insula', 'midline']\n3 (1.0%)\n\n\n    ['insula']\n9 (3.1%)\n\n\n    ['intra-axial', 'corpus callosum']\n1 (0.3%)\n\n\n    ['intra-axial', 'midline', 'basal ganglia']\n1 (0.3%)\n\n\n    ['intra-axial']\n8 (2.7%)\n\n\n    ['intraparenchyma']\n1 (0.3%)\n\n\n    ['intraventricular']\n3 (1.0%)\n\n\n    ['left insula', 'thalamus']\n1 (0.3%)\n\n\n    ['midbrain', 'basal ganglia', 'corpus callosum']\n1 (0.3%)\n\n\n    ['midbrain', 'corpus callosum']\n1 (0.3%)\n\n\n    ['midline', 'corpus callosum']\n1 (0.3%)\n\n\n    ['midline', 'right lateral ventricle']\n1 (0.3%)\n\n\n    ['midline']\n12 (4.1%)\n\n\n    ['optic nerve', 'optic tract', 'hypothalamus', 'basal ganglia']\n1 (0.3%)\n\n\n    ['optic nerve']\n1 (0.3%)\n\n\n    ['periventricular region', 'corpus callosum']\n1 (0.3%)\n\n\n    ['periventricular', 'corpus callosum']\n1 (0.3%)\n\n\n    ['pons', 'cerebellar peduncle']\n1 (0.3%)\n\n\n    ['pontomesencephalic junction']\n1 (0.3%)\n\n\n    ['postcentral gyrus', 'intra-axial']\n1 (0.3%)\n\n\n    ['spinal cord']\n1 (0.3%)\n\n\n    ['thalamus', 'basal ganglia']\n1 (0.3%)\n\n\n    ['thalamus', 'corpus callosum']\n1 (0.3%)\n\n\n    ['thalamus', 'hippocampus', 'insula']\n1 (0.3%)\n\n\n    ['thalamus', 'midbrain', 'basal ganglia']\n1 (0.3%)\n\n\n    ['thalamus', 'midbrain']\n1 (0.3%)\n\n\n    ['thalamus']\n13 (4.4%)\n\n\n    []\n163 (55%)\n\n\nleft insula\n1 (0.3%)\n\n\nsubinsular region\n1 (0.3%)\n\n\nintra-axial\n13 (4.4%)\n\n\nbasal ganglia\n26 (8.8%)\n\n\nbrainstem (cerebellum)\n1 (0.3%)\n\n\ncentrum semiovale\n1 (0.3%)\n\n\nhypothalamus\n2 (0.7%)\n\n\nperiventricular region\n1 (0.3%)\n\n\npontomesencephalic junction\n1 (0.3%)\n\n\nmidbrain\n5 (1.7%)\n\n\nperiventricular\n1 (0.3%)\n\n\nperi-insular\n1 (0.3%)\n\n\nintrahemispheric\n1 (0.3%)\n\n\nspinal cord\n1 (0.3%)\n\n\ncerebellum\n4 (1.4%)\n\n\npostcentral gyrus\n1 (0.3%)\n\n\nmidline\n24 (8.2%)\n\n\ninsula\n16 (5.4%)\n\n\nganglia thalamic capsule\n1 (0.3%)\n\n\nhippocampus\n5 (1.7%)\n\n\ncorpus callosum\n43 (15%)\n\n\ncerebellar peduncle\n1 (0.3%)\n\n\noptic nerve\n2 (0.7%)\n\n\nfalcine dural-based mass\n1 (0.3%)\n\n\ncaudate\n1 (0.3%)\n\n\nintraventricular\n3 (1.0%)\n\n\nright lateral ventricle\n1 (0.3%)\n\n\npons\n3 (1.0%)\n\n\noptic tract\n1 (0.3%)\n\n\nparafalcine lesions\n1 (0.3%)\n\n\ncorona radiatia\n1 (0.3%)\n\n\nintraparenchyma\n1 (0.3%)\n\n\nbrainstem\n2 (0.7%)\n\n\nthalamus\n27 (9.2%)\n\n\nstatus\n210 (72%)\n\n\n    Unknown\n3\n\n\n\n1 Median (Q1, Q3); n (%)"
  },
  {
    "objectID": "initial_pres.html",
    "href": "initial_pres.html",
    "title": "Initial Analysis",
    "section": "",
    "text": "Initial Analysis\n\nOverall Survival\nThis is a general picture of the overall survival of everyone in the data set. The red line represents the median value.\n\n\n\n\n\n\n\n\n\n\n\n\nSignificant Variables\nBelow are all of the individually significant variables I found in the dataset.\n\n\n\n\n\n\n\n\nvariable\np_value\n\n\n\n\nnum_radiations\n0.000000e+00\n\n\nnum_chemo\n0.000000e+00\n\n\nreceived_stupp\n1.063594e-13\n\n\ndiscontinued_stupps\n1.701831e-08\n\n\nnum_surgeries\n2.573419e-08\n\n\nresection_extent\n7.610069e-08\n\n\ndiscontinued_treatment\n7.401595e-07\n\n\ncaris\n8.531733e-03\n\n\nMGMT_methylation\n2.720695e-02\n\n\ntemporal\n2.982019e-02\n\n\n\n\n\n\n\n\n\nK-M Curves for Sig Variables\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n no yes \n261  10"
  }
]